|Title||Increased yield of endothelial cells from peripheral blood for cell therapies and tissue engineering.|
|Publication Type||Journal Article|
|Year of Publication||2015|
|Authors||RM Jamiolkowski, SD Kang, AK Rodriguez, JM Haseltine, LJ Galinat, AE Jantzen, TA Carlon, MD Darrabie, AJ Arciniegas, JG Mantilla, NR Haley, M Noviani, JD Allen, TV Stabler, JW Frederiksen, O Alzate, LG Keil, S Liu, F-H Lin, GA Truskey, and HE Achneck|
|Pagination||447 - 460|
Peripheral blood-derived endothelial cells (pBD-ECs) are an attractive tool for cell therapies and tissue engineering, but have been limited by their low isolation yield. We increase pBD-EC yield via administration of the chemokine receptor type 4 antagonist AMD3100, as well as via a diluted whole blood incubation (DWBI).Porcine pBD-ECs were isolated using AMD3100 and DWBI and tested for EC markers, acetylated LDL uptake, growth kinetics, metabolic activity, flow-mediated nitric oxide production and seeded onto titanium tubes implanted into vessels of pigs.DWBI increased the yield of porcine pBD-ECs 6.6-fold, and AMD3100 increased the yield 4.5-fold. AMD3100-mobilized ECs were phenotypically indistinguishable from nonmobilized ECs. In porcine implants, the cells expressed endothelial nitric oxide synthase, reduced thrombin-antithrombin complex systemically and prevented thrombosis.Administration of AMD3100 and the DWBI method both increase pBD-EC yield.
|Short Title||Regenerative Medicine|